Article
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.
Remdesivir
All News
Article
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
Article
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.
Article
Mease and colleagues have reviewed the tofacitinib drug development and clinical trial data, finding the risk of venous (VTE) and arterial thromboembolism (ATE) to be low and augmented in patients with baseline cardiovascular abd VTE risk factors and those taking higher doses of tofacitinib (10 m
Article
A large RA cohort study from the Swedish Rheumatology Quality Register shows a higher risk of venous thromboembolism (VTE) in rheumatoid arthritis (RA) and that risk is linked to RA disease activity.
Article
JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.
sheila
Tweet
Year in review by @JYazdanyMD ENTRACTE trial: CV safety of TCZ vs. ETN >similar CV events >TCZ grp slightly more infections & GI perforations @RheumNow #ACR20 https://t.co/yBDeHBDB3Z
CreakyJoints.org
Tweet
Lung disease in primary #SjogrensSyndrome is common; both conditions were diagnosed at the same time in 43% of patients, found an #ACR20 study from @joannamarco @GGRheumdoc + @UW @uofcincy colleagues. “Close monitoring is warranted” to make sure lung function is not declining. https://t.co/MpA0Rq2uVR
David Liew
Tweet
UK Biobank data: RA is associated with not just restrictive but also *obstructive* patterns on spirometry/PFTs (independent of smoking).
Consistent observation; direction of causality? The lung in RA continues to fascinate.
Prisco @jeffsparks et al #ACR20 ABST0491 @RheumNow https://t.co/LcjtAefnVF
Janet Pope
Tweet
ILD in SSc has grave consequences. Abstr#393 Claims database in Ontario shows relevant Scleroderma ILD occurred in 17% of >3000 pts with nearly double the mortality #ACR20 @RheumNow @CRASCRRheum #bestinclass https://t.co/K3UXvuxBcp
k dao
Tweet
#ACR20 Abstr#0433 #PlenaryACR Georgia SLE registry 336 pts ⬆️stroke/isch heart dz with:
👉3X stroke risk and 24X IHD risk for black pts
👉predictors stroke: black race, DLE, renal dz
👉predictors IHD: age>65, black race, neuro & immuno d/o (e.g, APAs)
@RheumNow https://t.co/u6Ky7r0FYF
Bella Mehta
Tweet
Plenary session 1 no#2F011 #ACR20 @rheumnow
Black #SLE patients have a 3 fold higher stroke and 24 fold higher Ishemic Heart Disease risk! https://t.co/AYtiXk7pDa
Richard Conway
Tweet
Dr Fernandez-Diaz on abatacept in RA-ILD in 263 patients. Abatacept appears safe and effective. Equivalent to RTX. Good option as s/c admin @rheumnow #ACR20 Abstr#0233 #ACRbest https://t.co/LfjqZpnGCh
David Liew
Tweet
When prescribing hydroxychloroquine for RA, SLE, or other rheumatic diseases, do you routinely order an EKG (either before or during)? #ACR20 @RheumNow
sheila
Tweet
Using #MachineLearning, multimorbidity patterns predominant for #rheumatoid arthritis: cardiometabolic, cardiopulmonary & #Mentalhealth/pain disorders. Patterns similar to non-RA pts but prevalence higher in RA pts. @RheumNow #ACR20 abstr#0179 https://t.co/zfCxzKquDV
Janet Pope
Tweet
What do you do with pharmacist drug alert for antimalarial cardiac safety &/or drug interactions @RheumNow #ACR2020 @CRASCRRheum
Peter Nash
Tweet
Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators) https://t.co/LGERY3mpe5 #febuxostat #allopurinol #CVS some cardiac reassurance feboxustat
Dr. John Cush
Tweet
Swedish population studied CV risk, studied gout. Among 22,057, 910 (4.1%) developed incident gout by 27.5 yrs w/ 5 Clusters: C1 no/few comorb; C2 had CKD; C3 CV dz; C4 obesity, dyslipidemia; C5 DM, HTN, diuretics. 86% of incident gout came from C1 & C4 https://t.co/TeMdXx5qU1
Dr. John Cush
Tweet
EUSTAR study of ILD in systemic sclerosis: 826 pts with SSc-ILD finds 27% with progressive ILD (mod-severe FVC decline >5-10%) over 12 mos. Predictive factors for FVC decline over 5 yrs were male sex, higher mRSS skin score and reflux/dysphagia symptoms. https://t.co/lLd2FrMIkx
Dr. John Cush
Tweet
Study of 196 RA pts shows lung Dz common by chest CT, regardless of serostatus. RA lung=higher mortality (HR of 5.3). RA lung dz found in 28%; 16% had ILD, 14% bronchiectasis, 9.5% w pleural dz. RA lung dz in both seropositive (29%) & seronegative (28%) https://t.co/upNX7cvlWq
